Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer

NCT03433469 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03433469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03433469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 31, 2018
Completion date
September 30, 2027
Enrollment
27 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stage i non-small cell lung cancer, stage ia non-small cell lung cancer, stage ib non-small cell lung cancer, stage ii non-small cell lung cancer, stage iia non-small cell lung cancer, stage iib non-small cell lung cancer, stage iiia non-small cell lung cancer